03422nam 22005774a 450 991014414250332120230617005329.01-281-32237-797866113223730-470-75150-90-470-75149-5(CKB)1000000000536040(EBL)351646(OCoLC)476173140(SSID)ssj0000266801(PQKBManifestationID)11226110(PQKBTitleCode)TC0000266801(PQKBWorkID)10305044(PQKB)11624785(MiAaPQ)EBC351646(Au-PeEL)EBL351646(CaPaEBR)ebr10233014(CaONFJC)MIL132237(EXLCZ)99100000000053604020050324d2005 uy 0engur|n|---|||||txtccrVascular complications of diabetes[electronic resource] current issues in pathogenesis and treatment /editor, Richard Donnelly ; associate editor, Edward Horton2nd ed.Malden, Mass. Blackwell Pub.20051 online resource (242 p.)Description based upon print version of record.1-4051-2785-6 Includes bibliographical references and index.The public health impact of the diabetes epidemic -- Risk factors -- Diabetic nephropathy -- Coronary heart disease and diabetes -- Diabetes and cerebrovascular disease -- Erectile dysfunction -- Evidence-based interventions to prevent or retard vascular complications -- Classification and clinical features of neuropathy -- Pathophsiology [sic] of diabetic neuropathy -- Epidemiology and natural history of DPN -- Detections/screenings/assessment -- Foot ulceration and charcot arthropathy -- Treatment options -- Management guidelines for diabetic peripheral neuropathy and foot ulceration -- Diabetic retinopathy: epidemiology and risk factors -- Classification and diagnosis of diabetic retinopathy -- Diabetic maculopathy -- Proliferative diabetic retinopathy -- Non-retinal diabetic ocular complications -- Pathophysiology & potential targets for therapeutic intervention -- Protein kinase C -- PKC activation & vascular permeability -- Role of PKC activation in cardiovascular and renal complications of diabetes -- Experimental pharmacology using isoform-selective PKC inhibitors -- Clinical trials with ruboxistaurin.Diabetes has reached epidemic proportions, and the cardiovascular complications of diabetes are life-threatening and disabling. This book is unique in providing a simple explanation of the biochemical role of PKC in diabetes complications, which allows clinicians to understand why PKC inhibitors (in development) are an exciting prospect for future treatment to slow progression of eye & foot complications. New features of this Second Edition include:Updated throughout to reflect the impact of recent major clinical trials on current clinical practice IncludeDiabetic angiopathiesDiabetic angiopathies.616.1/3Donnelly Richard1960-224728Horton Edward S864981MiAaPQMiAaPQMiAaPQBOOK9910144142503321Vascular complications of diabetes1930548UNINA